Cargando…

Mesothelin Binding to CA125/MUC16 Promotes Pancreatic Cancer Cell Motility and Invasion via MMP-7 Activation

Mesothelin (MSLN) and cancer antigen125/mucin 16 (CA125/MUC16) are potential biomarkers for pancreatic cancer (PC) that are co-overexpressed at the invading edges of PC tissues, and their expression correlates with poor survival rates. However, the role of MSLN-MUC16 molecular interaction in PC cell...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chen, Shih-Hsun, Hung, Wei-Chien, Wang, Pu, Paul, Colin, Konstantopoulos, Konstantinos
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2013
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3660778/ https://www.ncbi.nlm.nih.gov/pubmed/23694968 http://dx.doi.org/10.1038/srep01870

Ejemplares similares

Co-expression of mesothelin and CA125/MUC16 is a prognostic factor for breast cancer, especially in luminal-type breast cancer patients
por: Einama, Takahiro, et al.
Publicado: (2021)

Individual recombinant repeats of MUC16 display variable binding to CA125 antibodies
por: Wang, Chien-Wei, et al.
Publicado: (2023)

CA125/MUC16 Is Dispensable for Mouse Development and Reproduction
por: Cheon, Dong-Joo, et al.
Publicado: (2009)

Polymorphisms of MUC16 (CA125) and MUC1 (CA15.3) in Relation to Ovarian Cancer Risk and Survival
por: Williams, Kristina A., et al.
Publicado: (2014)

NAV-001, a high-efficacy antibody-drug conjugate targeting mesothelin with improved delivery of a potent payload by counteracting MUC16/CA125 inhibitory effects
por: Nicolaides, Nicholas C., et al.
Publicado: (2023)

Do mesothelin/MUC16 interactions facilitate adenocarcinoma metastases to intracranial meningiomas?
por: Johnson, Mahlon D.
Publicado: (2016)

Conflicting Views on the Molecular Structure of the Cancer Antigen CA125/MUC16
por: Bouanene, Houda, et al.
Publicado: (2010)

Significance of mesothelin and CA125 expression in endometrial carcinoma: a retrospective analysis
por: Kakimoto, Soichiro, et al.
Publicado: (2021)

MUC16 (CA125): tumor biomarker to cancer therapy, a work in progress
por: Felder, Mildred, et al.
Publicado: (2014)

Knockdown of MUC16 (CA125) Enhances the Migration and Invasion of Hepatocellular Carcinoma Cells
por: Huang, Yao, et al.
Publicado: (2021)

Expression of the Carboxy-Terminal Portion of MUC16/CA125 Induces Transformation and Tumor Invasion
por: Rao, Thapi D., et al.
Publicado: (2015)

Expression of MUC16/CA125 Is Associated with Impaired Survival in Patients with Surgically Resected Cholangiocarcinoma
por: Kinzler, Maximilian N., et al.
Publicado: (2022)

Mesothelin-MUC16 binding is a high affinity, N-glycan dependent interaction that facilitates peritoneal metastasis of ovarian tumors
por: Gubbels, Jennifer AA, et al.
Publicado: (2006)

The Potential Role of MUC16 (CA125) Biomarker in Lung Cancer: A Magic Biomarker but with Adversity
por: Saad, Hebatallah M., et al.
Publicado: (2022)

A Novel Survival-Based Tissue Microarray of Pancreatic Cancer Validates MUC1 and Mesothelin as Biomarkers
por: Winter, Jordan M., et al.
Publicado: (2012)

MUC16/CA125 in the Context of Modular Proteins with an Annotated Role in Adhesion-Related Processes: In Silico Analysis
por: Jankovic, Miroslava, et al.
Publicado: (2012)

Correction: A Novel Survival-Based Tissue Microarray of Pancreatic Cancer Validates MUC1 and Mesothelin as Biomarkers
por: Winter, Jordan M., et al.
Publicado: (2012)

Mesothelin's minimal MUC16 binding moiety converts TR3 into a potent cancer therapeutic via hierarchical binding events at the plasma membrane
por: Su, Yang, et al.
Publicado: (2016)

Eradicating mesothelin-positive human gastric and pancreatic tumors in xenograft models with optimized anti-mesothelin antibody–drug conjugates from synthetic antibody libraries
por: Hsu, Hung-Ju, et al.
Publicado: (2021)

HN125: A Novel Immunoadhesin Targeting MUC16 with Potential for Cancer Therapy
por: Xiang, Xinran, et al.
Publicado: (2011)

Pathobiological Implications of MUC16 Expression in Pancreatic Cancer
por: Haridas, Dhanya, et al.
Publicado: (2011)

Overexpression of Mesothelin in Pancreatic Ductal Adenocarcinoma (PDAC)
por: Le, Kai, et al.
Publicado: (2020)

Low serum mesothelin in pancreatic cancer patients results from retention of shed mesothelin in the tumor microenvironment
por: Zhang, Xianyu, et al.
Publicado: (2022)

Expression of KOC, S100P, mesothelin and MUC1 in pancreatico-biliary adenocarcinomas: development and utility of a potential diagnostic immunohistochemistry panel
por: Ali, Asif, et al.
Publicado: (2014)

Diagnostic value of pleural fluid SMRP, CA125, MMP-7, and MMP-9 in malignant pleural effusion
por: Han, Gaohua, et al.
Publicado: (2023)

Expression of CA125 in pancreatic carcinoma and chronic pancreatitis.
por: Macdonald, F., et al.
Publicado: (1988)

MUC16 mucin (CA125) attenuates TRAIL-induced apoptosis by decreasing TRAIL receptor R2 expression and increasing c-FLIP expression
por: Matte, Isabelle, et al.
Publicado: (2014)

High mutation load, immune-activated microenvironment, favorable outcome, and better immunotherapeutic efficacy in melanoma patients harboring MUC16/CA125 mutations
por: Wang, Qinghua, et al.
Publicado: (2020)

Characterization of human mesothelin transcripts in ovarian and pancreatic cancer
por: Muminova, Zhanat E, et al.
Publicado: (2004)

Characterization of the tumor marker muc16 (ca125) expressed by murine ovarian tumor cell lines and identification of a panel of cross-reactive monoclonal antibodies
por: Goodell, Cara AR, et al.
Publicado: (2009)

Downregulation of cell surface CA125/MUC16 induces epithelial-to-mesenchymal transition and restores EGFR signalling in NIH:OVCAR3 ovarian carcinoma cells
por: Comamala, M, et al.
Publicado: (2011)

Tumor necrosis factor-α and interferon-γ stimulate MUC16 (CA125) expression in breast, endometrial and ovarian cancers through NFκB
por: Morgado, Micaela, et al.
Publicado: (2016)

Targeting galectin-3 with a high-affinity antibody for inhibition of high-grade serous ovarian cancer and other MUC16/CA-125-expressing malignancies
por: Stasenko, Marina, et al.
Publicado: (2021)

Serum folate receptor alpha, mesothelin and megakaryocyte potentiating factor in ovarian cancer: association to disease stage and grade and comparison to CA125 and HE4
por: O’Shannessy, Daniel J, et al.
Publicado: (2013)

Free CA125 promotes ovarian cancer cell migration and tumor metastasis by binding Mesothelin to reduce DKK1 expression and activate the SGK3/FOXO3 pathway
por: Huo, Qianyu, et al.
Publicado: (2021)

Highly active CAR T cells that bind to a juxtamembrane region of mesothelin and are not blocked by shed mesothelin
por: Liu, Xiufen, et al.
Publicado: (2022)

Methylation-Associated Partial Down-Regulation of Mesothelin Causes Resistance to Anti-Mesothelin Immunotoxins in a Pancreatic Cancer Cell Line
por: Hollevoet, Kevin, et al.
Publicado: (2015)

Development of improved therapeutic mesothelin-based vaccines for pancreatic cancer
por: White, Michael, et al.
Publicado: (2018)

Mesothelin-Specific Immune Responses and Targeted Immunotherapy for Mesothelin-Expressing Tumors
por: Einama, Takahiro, et al.
Publicado: (2017)

Histoepigenetic analysis of the mesothelin network within pancreatic ductal adenocarcinoma cells reveals regulation of retinoic acid receptor gamma and AKT by mesothelin
por: Lurie, Eugene, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_f3sbiqpdecepkl08tim574lo9l